We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more

Link to third party site

The link you have selected will take you away from this site to one that is not owned or controlled by Roche, F. Hoffmann-La Roche Ltd makes no representation as to the accuracy of the information contained on sites we do not own or control. Roche does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

364 Search Results

Reappearance of inhibitor in a tolerized patient with severe haemophilia A during FVIII-free emicizumab therapy

Capdevila L, Borgel D, Lasne D, et al. Haemophilia. 2021 Jul;27(4):e581-e584

Spinal epidural hematoma in a child with hemophilia A with high titer inhibitors and follow-up with prophylactic emicizumab: case report and literature review

Villarreal-Martínez L, Sepúlveda-Orozco MDC, García-Viera DA, et al. Blood Coagul Fibrinolysis. 32(6):418-422, September 2021.

Severe bleeding after haemorrhoidal banding in a haemophilia patient treated with emicizumab

Barish J, Hajdenberg J. Haemophilia. 2021 Jul;27(4):e589-e590

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database

Peyvandi F, Mahlangu JN, Pipe SW et al. J Thromb Haemost. 2021;19(Suppl. 1):32-41.

Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII‐equivalence.

Leksa NC, Aleman MM, Goodman AG, et al. J Thromb Haemost 2019;17:1044–1052.    

Long-term outcomes with emicizumab prophylaxis for hemophilia A with/without FVIII inhibitors from the HAVEN 1-4 studies

Callaghan MU, Negrier CG, Paz-Priel I. Blood. 2021 Apr 22;137(16):2231-2242.

Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays.

Adamkewicz JI, Chen DC and Paz-Priel I. Thromb Haemost 2019;119:1084–1093.

Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study

Yu JK, Iorio A, Chelle P, Edginton AN. Haemophilia. 2021 May;27(3):358-365

Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban

Tripodi A, Chantarangkul V, Padovan L, Clerici M, Scalambrino E, Peyvandi F. J Thromb Thrombolysis. 2020;49(3):413-419.

Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A

Shima M, Hanabusa H, Taki M, et al. N Engl J Med. 2016;374(21):2044-2053.